Angela C Baird1, Frances Lloyd, Ian C Lawrance. 1. Fremantle Unit, School of Medicine and Pharmacology, Level 6, T Block, Fremantle Hospital, University of Western Australia, Alma Street, Fremantle, WA, 6010, Australia, angela.chew@uwa.edu.au.
Abstract
BACKGROUND: Intestinal fibrosis is a serious and often recurrent complication of inflammatory bowel disease despite surgical intervention. The anti-fibrotic potential of prostaglandin E2 (PGE2) and polyenylphosphatidylcholine (PC) was investigated using the murine model of 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced chronic intestinal inflammation and fibrosis, and murine and human intestinal myofibroblasts. METHODS: Mice were treated with TNBS enemas weekly for 2 or 6 weeks ± PGE2 (10 mg/kg/day orally) or PC (200 mg/kg/day orally). Inflammation and fibrosis were histologically assessed and scored. Pro-inflammatory cytokines, TLR4, and ECM-related gene expression from the colonic tissue and cultured myofibroblasts were assessed by RT-qPCR. The levels of α-SMA(+) staining and endogenous PGE2 in vivo were also assessed. RESULTS: Both PGE2 and PC treatment significantly decreased TNBS-induced intestinal inflammation and excess collagen deposition in vivo. This was accompanied by decreased α-SMA(+) staining in the lamina propria and lower collagen type I (COL1α1) expression. Endogenous PGE2 levels demonstrated that PC was not being converted into PGE2, thus mediating its effects primarily via PGE2-independent pathways. Both PGE2 and the PC isoform, 1,2-dilinoleoylphosphatidylcholine (DLPC), regulated primary mouse myofibroblast and CCD-18co COL1α1 production, and induced lower collagen type I to III and TGF-β1 to TGF-β3 ratios, demonstrating their ability to induced normal healing in the presence of phorbol 12-myristate 13-acetate (protein kinase C-dependent inducer of collagen production). CONCLUSION: PGE2 and PC both have potent anti-fibrogenic potentials in their ability to regulate inflammatory cell and myofibroblast accumulation within inflamed tissue, to decrease pro-inflammatory cytokine expression and to maintain normal healing in an inflammatory environment.
BACKGROUND: Intestinal fibrosis is a serious and often recurrent complication of inflammatory bowel disease despite surgical intervention. The anti-fibrotic potential of prostaglandin E2 (PGE2) and polyenylphosphatidylcholine (PC) was investigated using the murine model of 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced chronic intestinal inflammation and fibrosis, and murine and human intestinal myofibroblasts. METHODS:Mice were treated with TNBS enemas weekly for 2 or 6 weeks ± PGE2 (10 mg/kg/day orally) or PC (200 mg/kg/day orally). Inflammation and fibrosis were histologically assessed and scored. Pro-inflammatory cytokines, TLR4, and ECM-related gene expression from the colonic tissue and cultured myofibroblasts were assessed by RT-qPCR. The levels of α-SMA(+) staining and endogenous PGE2 in vivo were also assessed. RESULTS: Both PGE2 and PC treatment significantly decreased TNBS-induced intestinal inflammation and excess collagen deposition in vivo. This was accompanied by decreased α-SMA(+) staining in the lamina propria and lower collagen type I (COL1α1) expression. Endogenous PGE2 levels demonstrated that PC was not being converted into PGE2, thus mediating its effects primarily via PGE2-independent pathways. Both PGE2 and the PC isoform, 1,2-dilinoleoylphosphatidylcholine (DLPC), regulated primary mouse myofibroblast and CCD-18co COL1α1 production, and induced lower collagen type I to III and TGF-β1 to TGF-β3 ratios, demonstrating their ability to induced normal healing in the presence of phorbol 12-myristate 13-acetate (protein kinase C-dependent inducer of collagen production). CONCLUSION:PGE2 and PC both have potent anti-fibrogenic potentials in their ability to regulate inflammatory cell and myofibroblast accumulation within inflamed tissue, to decrease pro-inflammatory cytokine expression and to maintain normal healing in an inflammatory environment.
Authors: T Kohyama; R F Ertl; V Valenti; J Spurzem; M Kawamoto; Y Nakamura; T Veys; L Allegra; D Romberger; S I Rennard Journal: Am J Physiol Lung Cell Mol Physiol Date: 2001-11 Impact factor: 5.464
Authors: C B Keerthisingam; R G Jenkins; N K Harrison; N A Hernandez-Rodriguez; H Booth; G J Laurent; S L Hart; M L Foster; R J McAnulty Journal: Am J Pathol Date: 2001-04 Impact factor: 4.307
Authors: Bethany B Moore; Megan N Ballinger; Eric S White; Maranne E Green; Amy B Herrygers; Carol A Wilke; Galen B Toews; Marc Peters-Golden Journal: J Immunol Date: 2005-05-01 Impact factor: 5.422
Authors: Ian C Lawrance; Feng Wu; André Z A Leite; Joseph Willis; Gail A West; Claudio Fiocchi; Shukti Chakravarti Journal: Gastroenterology Date: 2003-12 Impact factor: 22.682
Authors: Jessica M Bradley; Pablo Spaletra; Zhen Li; Thomas E Sharp; Traci T Goodchild; Laura G Corral; Leah Fung; Kyle W H Chan; Robert W Sullivan; Cathy A Swindlehurst; David J Lefer Journal: Am J Physiol Heart Circ Physiol Date: 2018-06-27 Impact factor: 4.733